Literature DB >> 19097226

A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study.

Volker J Schmid1, Brandon Whitcher, Anwar R Padhani, N Jane Taylor, Guang-Zhong Yang.   

Abstract

Imaging in clinical oncology trials provides a wealth of information that contributes to the drug development process, especially in early phase studies. This article focuses on kinetic modeling in DCE-MRI, inspired by mixed-effects models that are frequently used in the analysis of clinical trials. Instead of summarizing each scanning session as a single kinetic parameter--such as median k(trans) across all voxels in the tumor ROI-we propose to analyze all voxel time courses from all scans and across all subjects simultaneously in a single model. The kinetic parameters from the usual nonlinear regression model are decomposed into unique components associated with factors from the longitudinal study; e.g., treatment, patient, and voxel effects. A Bayesian hierarchical model provides the framework to construct a data model, a parameter model, as well as prior distributions. The posterior distribution of the kinetic parameters is estimated using Markov chain Monte Carlo (MCMC) methods. Hypothesis testing at the study level for an overall treatment effect is straightforward and the patient- and voxel-level parameters capture random effects that provide additional information at various levels of resolution to allow a thorough evaluation of the clinical trial. The proposed method is validated with a breast cancer study, where the subjects were imaged before and after two cycles of chemotherapy, demonstrating the clinical potential of this method to longitudinal oncology studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19097226     DOI: 10.1002/mrm.21807

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  7 in total

1.  A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.

Authors:  Brandon Whitcher; Volker J Schmid; David J Collins; Matthew R Orton; Dow-Mu Koh; Isabela Diaz de Corcuera; Marta Parera; Josep M del Campo; Nandita M DeSouza; Martin O Leach; Kevin Harrington; Iman A El-Hariry
Journal:  MAGMA       Date:  2011-01-04       Impact factor: 2.310

2.  Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging.

Authors:  Stephen R Bowen; Daniel S Hippe; W Art Chaovalitwongse; Chunyan Duan; Phawis Thammasorn; Xiao Liu; Robert S Miyaoka; Hubert J Vesselle; Paul E Kinahan; Ramesh Rengan; Jing Zeng
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

3.  Assessing antiangiogenic therapy response by DCE-MRI: development of a physiology driven multi-compartment model using population pharmacometrics.

Authors:  Andreas Steingoetter; Dieter Menne; Rickmer F Braren
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

4.  Models of the aging brain structure and individual decline.

Authors:  Gabriel Ziegler; Robert Dahnke; Christian Gaser
Journal:  Front Neuroinform       Date:  2012-03-14       Impact factor: 4.081

5.  DCEMRI.jl: a fast, validated, open source toolkit for dynamic contrast enhanced MRI analysis.

Authors:  David S Smith; Xia Li; Lori R Arlinghaus; Thomas E Yankeelov; E Brian Welch
Journal:  PeerJ       Date:  2015-04-23       Impact factor: 2.984

6.  Estimating anatomical trajectories with Bayesian mixed-effects modeling.

Authors:  G Ziegler; W D Penny; G R Ridgway; S Ourselin; K J Friston
Journal:  Neuroimage       Date:  2015-07-17       Impact factor: 6.556

7.  Direct Comparison of Bayesian and Fermi Deconvolution Approaches for Myocardial Blood Flow Quantification: In silico and Clinical Validations.

Authors:  Clément Daviller; Timothé Boutelier; Shivraman Giri; Hélène Ratiney; Marie-Pierre Jolly; Jean-Paul Vallée; Pierre Croisille; Magalie Viallon
Journal:  Front Physiol       Date:  2021-04-12       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.